A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse

In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model

(2015) Libo Zhang et al.   NEOPLASIA

Antiangiogenesis Enhances Intratumoral Drug Retention

(2011) J. Ma et al.   CANCER RESEARCH

Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Optimization of vincristine–topotecan combination — Paving the way for improved chemotherapy regimens by nanoliposomes

(2010) Daniel Zucker et al.   JOURNAL OF CONTROLLED RELEASE

All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells

(2010) Ruo-Jing Li et al.   JOURNAL OF CONTROLLED RELEASE

Octreotide-Targeted Liposomes Loaded with CPT-11 Enhanced Cytotoxicity for the Treatment of Medullary Thyroid Carcinoma

(2010) Yuko Iwase et al.   MOLECULAR PHARMACEUTICS

Liposomal imatinib-mitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer

(2010) Ana Catarina Pinto et al.   PROSTATE

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

(2009) Joshua Ö. Haznedar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma

(2009) Benoit Blanchet et al.   CLINICA CHIMICA ACTA

Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma

(2009) H. Huynh et al.   CURRENT CANCER DRUG TARGETS

Malignant Pheochromocytomas and Paragangliomas: Molecular Signaling Pathways and Emerging Therapies

(2009) L. Santarpia et al.   HORMONE AND METABOLIC RESEARCH

Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma

(2009) K.-S. Park et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors

(2009) Yoshiyuki Hattori et al.   JOURNAL OF CONTROLLED RELEASE

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo

(2009) P. G. Tardi et al.   MOLECULAR CANCER THERAPEUTICS

Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors

(2008) E. C. Ramsay et al.   CLINICAL CANCER RESEARCH

Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy

(2008) Marcus Czabanka et al.   INTERNATIONAL JOURNAL OF CANCER

Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes

(2008) Y. Katanasaka et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors

(2008) Camilo Jimenez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM